Capecitabine, oxaliplatin and radiotherapy: A phase IB neoadjuvant study for esophageal cancer with gene expression analysis

Milind M. Javle; Gary Yang; Chumy E. Nwogu; Gregory E. Wilding; Linda O'Malley; Sanjay Vinjamaram; Michael D. Schiff; Hector R. Nava; Charles LeVea; Kimberly R. Clark; Joshua D. Prey; Patrick F. Smith; Lakshmi Pendyala

doi:10.1080/07357900802172093

Capecitabine, oxaliplatin and radiotherapy: A phase IB neoadjuvant study for esophageal cancer with gene expression analysis

Milind M. Javle
, Gary Yang
, Chumy E. Nwogu
, Gregory E. Wilding
, Linda O'Malley
, Sanjay Vinjamaram
, Michael D. Schiff
, Hector R. Nava
, Charles LeVea
, Kimberly R. Clark
, Joshua D. Prey
, Patrick F. Smith
, Lakshmi Pendyala

University of Texas MD Anderson Cancer Center
Roswell Park Cancer Institute

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Purpose: To determine the maximal tolerated dose of capecitabine with oxaliplatin + radiotherapy in a phase I study of localized esophageal cancer. Patients and Methods: Oxaliplatin (85 mg/m2) administered on days 1, 15, and 29. Capecitabine administered twice daily 5 days weekly; dose levels (DL) were 1, 1000; 2, 1250; and 3, 1500 mg/m2 with 50.4 Gy radiation. Results: Dose-limiting toxicity was reached at DL 3. Carboxylesterase expression in day 2 tumor specimens and induction correlated with response (p ≤ 0.05). Conclusion: The maximal tolerated dose was 85 mg/m2 of oxaliplatin, 1,250 mg/m2/day of capecitabine, and 50.4 Gy of radiation.

Original language	English
Pages (from-to)	193-200
Number of pages	8
Journal	Cancer Investigation
Volume	27
Issue number	2
DOIs	https://doi.org/10.1080/07357900802172093
State	Published - Feb 2009

Keywords

Capecitabine
Esophageal neoplasms
Gene expression
Neoadjuvant therapy
Oxaliplatin

Access to Document

10.1080/07357900802172093

Cite this

Javle, M. M., Yang, G., Nwogu, C. E., Wilding, G. E., O'Malley, L., Vinjamaram, S., Schiff, M. D., Nava, H. R., LeVea, C., Clark, K. R., Prey, J. D., Smith, P. F., & Pendyala, L. (2009). Capecitabine, oxaliplatin and radiotherapy: A phase IB neoadjuvant study for esophageal cancer with gene expression analysis. Cancer Investigation, 27(2), 193-200. https://doi.org/10.1080/07357900802172093

@article{a834a03401134bd8b13a42fcb43b1a8d,

title = "Capecitabine, oxaliplatin and radiotherapy: A phase IB neoadjuvant study for esophageal cancer with gene expression analysis",

abstract = "Purpose: To determine the maximal tolerated dose of capecitabine with oxaliplatin + radiotherapy in a phase I study of localized esophageal cancer. Patients and Methods: Oxaliplatin (85 mg/m2) administered on days 1, 15, and 29. Capecitabine administered twice daily 5 days weekly; dose levels (DL) were 1, 1000; 2, 1250; and 3, 1500 mg/m2 with 50.4 Gy radiation. Results: Dose-limiting toxicity was reached at DL 3. Carboxylesterase expression in day 2 tumor specimens and induction correlated with response (p ≤ 0.05). Conclusion: The maximal tolerated dose was 85 mg/m2 of oxaliplatin, 1,250 mg/m2/day of capecitabine, and 50.4 Gy of radiation.",

keywords = "Capecitabine, Esophageal neoplasms, Gene expression, Neoadjuvant therapy, Oxaliplatin",

author = "Javle, \{Milind M.\} and Gary Yang and Nwogu, \{Chumy E.\} and Wilding, \{Gregory E.\} and Linda O'Malley and Sanjay Vinjamaram and Schiff, \{Michael D.\} and Nava, \{Hector R.\} and Charles LeVea and Clark, \{Kimberly R.\} and Prey, \{Joshua D.\} and Smith, \{Patrick F.\} and Lakshmi Pendyala",

year = "2009",

month = feb,

doi = "10.1080/07357900802172093",

language = "English",

volume = "27",

pages = "193--200",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Taylor \& Francis Group LLC Philadelphia",

number = "2",

}

Javle, MM, Yang, G, Nwogu, CE, Wilding, GE, O'Malley, L, Vinjamaram, S, Schiff, MD, Nava, HR, LeVea, C, Clark, KR, Prey, JD, Smith, PF & Pendyala, L 2009, 'Capecitabine, oxaliplatin and radiotherapy: A phase IB neoadjuvant study for esophageal cancer with gene expression analysis', Cancer Investigation, vol. 27, no. 2, pp. 193-200. https://doi.org/10.1080/07357900802172093

TY - JOUR

T1 - Capecitabine, oxaliplatin and radiotherapy

T2 - A phase IB neoadjuvant study for esophageal cancer with gene expression analysis

AU - Javle, Milind M.

AU - Yang, Gary

AU - Nwogu, Chumy E.

AU - Wilding, Gregory E.

AU - O'Malley, Linda

AU - Vinjamaram, Sanjay

AU - Schiff, Michael D.

AU - Nava, Hector R.

AU - LeVea, Charles

AU - Clark, Kimberly R.

AU - Prey, Joshua D.

AU - Smith, Patrick F.

AU - Pendyala, Lakshmi

PY - 2009/2

Y1 - 2009/2

N2 - Purpose: To determine the maximal tolerated dose of capecitabine with oxaliplatin + radiotherapy in a phase I study of localized esophageal cancer. Patients and Methods: Oxaliplatin (85 mg/m2) administered on days 1, 15, and 29. Capecitabine administered twice daily 5 days weekly; dose levels (DL) were 1, 1000; 2, 1250; and 3, 1500 mg/m2 with 50.4 Gy radiation. Results: Dose-limiting toxicity was reached at DL 3. Carboxylesterase expression in day 2 tumor specimens and induction correlated with response (p ≤ 0.05). Conclusion: The maximal tolerated dose was 85 mg/m2 of oxaliplatin, 1,250 mg/m2/day of capecitabine, and 50.4 Gy of radiation.

AB - Purpose: To determine the maximal tolerated dose of capecitabine with oxaliplatin + radiotherapy in a phase I study of localized esophageal cancer. Patients and Methods: Oxaliplatin (85 mg/m2) administered on days 1, 15, and 29. Capecitabine administered twice daily 5 days weekly; dose levels (DL) were 1, 1000; 2, 1250; and 3, 1500 mg/m2 with 50.4 Gy radiation. Results: Dose-limiting toxicity was reached at DL 3. Carboxylesterase expression in day 2 tumor specimens and induction correlated with response (p ≤ 0.05). Conclusion: The maximal tolerated dose was 85 mg/m2 of oxaliplatin, 1,250 mg/m2/day of capecitabine, and 50.4 Gy of radiation.

KW - Capecitabine

KW - Esophageal neoplasms

KW - Gene expression

KW - Neoadjuvant therapy

KW - Oxaliplatin

UR - https://www.scopus.com/pages/publications/60849110846

U2 - 10.1080/07357900802172093

DO - 10.1080/07357900802172093

M3 - Article

C2 - 19235592

AN - SCOPUS:60849110846

SN - 0735-7907

VL - 27

SP - 193

EP - 200

JO - Cancer Investigation

JF - Cancer Investigation

IS - 2

ER -

Capecitabine, oxaliplatin and radiotherapy: A phase IB neoadjuvant study for esophageal cancer with gene expression analysis

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this